Type 2 Diabetes Mellitus
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Interventions
DRUGElecoglipron
Elecoglipron is administered orally once daily.
DRUGDapagliflozin
Dapagliflozin administered orally once daily.
A placebo matching elecoglipron administered orally once daily.
A placebo matching dapagliflozin administered orally once daily.
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening * T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication * HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol) * Body mass index (BMI) of ≥ 23 kg/m2 at screening * Stable body weight (self-reported or documented) for 90 days prior to screening
Exclusion criteria
* Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma * Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema * Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms * Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying * History of acute or chronic pancreatitis * Severe congestive heart failure (New York Heart Association IV) * History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in Hemoglobin A1c (HbA1c) | Baseline to Week 40 |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in Hemoglobin A1c (HbA1c) | Baseline to Week 40 |
| Achievement of HbA1c < 7% (53 mmol/mol) | Week 40 |
| Percent change in body weight | Baseline to Week 40 |
| Change from baseline in body weight | Baseline to Week 40 |
| Change from baseline in Fasting Plasma Glucose (FPG) | Baseline to Week 40 |
| Change from baseline in daily mean 7-point Self-Monitored Blood Glucose (SMBG) | Baseline to Week 40 |
| Achievement of ≥ 5% weight loss from baseline | Baseline to Week 40 |
| Change from baseline in Systolic Blood Pressure (SBP) | Baseline to Week 40 |
| Change from baseline in Diastolic Blood Pressure (DBP) | Baseline to Week 40 |
| Time to initiation of rescue medication over 40 weeks | Baseline to Week 40 |
Countries
Argentina, Brazil, China, Czechia, Denmark, Germany, Greece, Hungary, India, Japan, Malaysia, Mexico, Poland, Puerto Rico, South Africa, South Korea, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States, Vietnam
Contacts
CONTACTAstraZeneca Clinical Study Information Center
Outcome results
None listed